579 related articles for article (PubMed ID: 21067355)
1. Cost effectiveness of tyrosine kinase inhibitor therapy in metastatic gastrointestinal stromal tumors.
Blanke CD; Huse DM
J Med Econ; 2010; 13(4):681-90. PubMed ID: 21067355
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness analysis of sunitinib in patients with metastatic and/or unresectable gastrointestinal stroma tumours (GIST) after progression or intolerance with imatinib.
Paz-Ares L; García del Muro X; Grande E; González P; Brosa M; Díaz S
Clin Transl Oncol; 2008 Dec; 10(12):831-9. PubMed ID: 19068454
[TBL] [Abstract][Full Text] [Related]
3. Clinical efficacy of second-generation tyrosine kinase inhibitors in imatinib-resistant gastrointestinal stromal tumors: a meta-analysis of recent clinical trials.
Wu L; Zhang Z; Yao H; Liu K; Wen Y; Xiong L
Drug Des Devel Ther; 2014; 8():2061-7. PubMed ID: 25378911
[TBL] [Abstract][Full Text] [Related]
4. [Evidence-based treatment of gastrointestinal stromal tumor (GIST) with tyrosine kinase inhibitors-imatinib and sunitinib].
Nishida T; Omori T; Ueshima S
Gan To Kagaku Ryoho; 2011 May; 38(5):733-7. PubMed ID: 21566432
[TBL] [Abstract][Full Text] [Related]
5. Managing progressive disease in patients with GIST: factors to consider besides acquired secondary tyrosine kinase inhibitor resistance.
Patel S
Cancer Treat Rev; 2012 Aug; 38(5):467-72. PubMed ID: 22035971
[TBL] [Abstract][Full Text] [Related]
6. Clinical effectiveness and cost-effectiveness of imatinib dose escalation for the treatment of unresectable and/or metastatic gastrointestinal stromal tumours that have progressed on treatment at a dose of 400 mg/day: a systematic review and economic evaluation.
Hislop J; Quayyum Z; Elders A; Fraser C; Jenkinson D; Mowatt G; Sharma P; Vale L; Petty R
Health Technol Assess; 2011 Jun; 15(25):1-178. PubMed ID: 21689502
[TBL] [Abstract][Full Text] [Related]
7. Gastrointestinal stromal tumors: imatinib and beyond.
Schnadig ID; Blanke CD
Curr Treat Options Oncol; 2006 Nov; 7(6):427-37. PubMed ID: 17032555
[TBL] [Abstract][Full Text] [Related]
8. Tyrosine kinase inhibitors in the treatment of unresectable or metastatic gastrointestinal stromal tumors.
Nishida T; Doi T; Naito Y
Expert Opin Pharmacother; 2014 Oct; 15(14):1979-89. PubMed ID: 24990162
[TBL] [Abstract][Full Text] [Related]
9. The challenge of conducting pharmacoeconomic evaluations in oncology using crossover trials: the example of sunitinib for gastrointestinal stromal tumour.
Chabot I; LeLorier J; Blackstein ME
Eur J Cancer; 2008 May; 44(7):972-7. PubMed ID: 18372169
[TBL] [Abstract][Full Text] [Related]
10. Imatinib for the treatment of patients with unresectable and/or metastatic gastrointestinal stromal tumours: systematic review and economic evaluation.
Wilson J; Connock M; Song F; Yao G; Fry-Smith A; Raftery J; Peake D
Health Technol Assess; 2005 Jul; 9(25):1-142. PubMed ID: 15985189
[TBL] [Abstract][Full Text] [Related]
11. A pharmaco-economic analysis of second-line treatment with imatinib or sunitinib in patients with advanced gastrointestinal stromal tumours.
Contreras-Hernández I; Mould-Quevedo JF; Silva A; Salinas-Escudero G; Villasís-Keever MA; Granados-García V; Dávila-Loaiza G; Petersen JA; Garduño-Espinosa J
Br J Cancer; 2008 Jun; 98(11):1762-8. PubMed ID: 18506179
[TBL] [Abstract][Full Text] [Related]
12. Advances in the treatment of gastrointestinal stromal tumours.
Judson I; Demetri G
Ann Oncol; 2007 Sep; 18 Suppl 10():x20-4. PubMed ID: 17761719
[TBL] [Abstract][Full Text] [Related]
13. Recent advances in therapy for gastrointestinal stromal tumors.
Maki RG
Curr Oncol Rep; 2007 May; 9(3):165-9. PubMed ID: 17430686
[TBL] [Abstract][Full Text] [Related]
14. Cost effectiveness of imatinib mesylate in the treatment of advanced gastrointestinal stromal tumours.
Huse DM; von Mehren M; Lenhart G; Joensuu H; Blanke C; Feng W; Finkelstein S; Demetri G
Clin Drug Investig; 2007; 27(2):85-93. PubMed ID: 17217313
[TBL] [Abstract][Full Text] [Related]
15. Sunitinib for imatinib-resistant GIST.
Joensuu H
Lancet; 2006 Oct; 368(9544):1303-4. PubMed ID: 17046443
[No Abstract] [Full Text] [Related]
16. Novel approaches to imatinib- and sunitinib-resistant GIST.
Reichardt P
Curr Oncol Rep; 2008 Jul; 10(4):344-9. PubMed ID: 18778561
[TBL] [Abstract][Full Text] [Related]
17. Sunitinib treatment in pediatric patients with advanced GIST following failure of imatinib.
Janeway KA; Albritton KH; Van Den Abbeele AD; D'Amato GZ; Pedrazzoli P; Siena S; Picus J; Butrynski JE; Schlemmer M; Heinrich MC; Demetri GD
Pediatr Blood Cancer; 2009 Jul; 52(7):767-71. PubMed ID: 19326424
[TBL] [Abstract][Full Text] [Related]
18. Current management of gastrointestinal stromal tumors--a comprehensive review.
Lai EC; Lau SH; Lau WY
Int J Surg; 2012; 10(7):334-40. PubMed ID: 22633986
[TBL] [Abstract][Full Text] [Related]
19. Imatinib escalation or sunitinib treatment after first-line imatinib in metastatic gastrointestinal stromal tumor patients.
Hsu CC; Wu CE; Chen JS; Tseng JH; Chiang KC; Liu YY; Tsai CY; Cheng CT; Chen TW; Jan YY; Yeh TS; Chen YY; Yeh CN
Anticancer Res; 2014 Sep; 34(9):5029-36. PubMed ID: 25202087
[TBL] [Abstract][Full Text] [Related]
20. [Sunitinib as a second-line therapy for imatinib-resistant gastrointestinal stromal tumors].
Ishikawa T; Kanda T; Kosugi S; Yajima K; Hatakeyama K
Gan To Kagaku Ryoho; 2011 Jun; 38(6):916-21. PubMed ID: 21677482
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
